POZZI, ELEONORA
 Distribuzione geografica
Continente #
NA - Nord America 8.832
AS - Asia 7.025
EU - Europa 5.147
SA - Sud America 810
AF - Africa 110
OC - Oceania 41
Continente sconosciuto - Info sul continente non disponibili 7
Totale 21.972
Nazione #
US - Stati Uniti d'America 8.615
SG - Singapore 2.008
VN - Vietnam 1.982
CN - Cina 1.491
IT - Italia 1.315
DE - Germania 928
RU - Federazione Russa 840
HK - Hong Kong 760
BR - Brasile 676
SE - Svezia 548
IE - Irlanda 355
GB - Regno Unito 281
IN - India 145
CA - Canada 136
KR - Corea 130
AT - Austria 129
FI - Finlandia 127
FR - Francia 121
ID - Indonesia 115
UA - Ucraina 92
NL - Olanda 77
JP - Giappone 76
DK - Danimarca 72
LT - Lituania 71
TR - Turchia 70
AR - Argentina 54
BD - Bangladesh 53
MX - Messico 52
PL - Polonia 42
ES - Italia 40
AU - Australia 38
ZA - Sudafrica 37
BE - Belgio 32
EG - Egitto 28
IQ - Iraq 28
EC - Ecuador 25
TW - Taiwan 19
MY - Malesia 18
SA - Arabia Saudita 18
PY - Paraguay 17
PK - Pakistan 16
IR - Iran 13
RO - Romania 13
CZ - Repubblica Ceca 12
CH - Svizzera 11
CO - Colombia 10
TH - Thailandia 10
VE - Venezuela 10
AE - Emirati Arabi Uniti 9
IL - Israele 9
KZ - Kazakistan 9
DZ - Algeria 8
UZ - Uzbekistan 8
EU - Europa 7
AO - Angola 6
BG - Bulgaria 6
HR - Croazia 6
OM - Oman 6
RS - Serbia 6
UY - Uruguay 6
BO - Bolivia 5
HN - Honduras 5
MA - Marocco 5
NG - Nigeria 5
PH - Filippine 5
AZ - Azerbaigian 4
BN - Brunei Darussalam 4
CL - Cile 4
CR - Costa Rica 4
ET - Etiopia 4
JO - Giordania 4
KE - Kenya 4
LV - Lettonia 4
TN - Tunisia 4
AL - Albania 3
BH - Bahrain 3
HU - Ungheria 3
NI - Nicaragua 3
NP - Nepal 3
NZ - Nuova Zelanda 3
PA - Panama 3
PE - Perù 3
PS - Palestinian Territory 3
PT - Portogallo 3
SC - Seychelles 3
SK - Slovacchia (Repubblica Slovacca) 3
TT - Trinidad e Tobago 3
BB - Barbados 2
CU - Cuba 2
DO - Repubblica Dominicana 2
GR - Grecia 2
GT - Guatemala 2
JM - Giamaica 2
KG - Kirghizistan 2
KW - Kuwait 2
MD - Moldavia 2
BY - Bielorussia 1
CG - Congo 1
CM - Camerun 1
DM - Dominica 1
Totale 21.964
Città #
Ann Arbor 1.750
Dallas 1.501
Singapore 1.255
Ashburn 782
Hong Kong 753
Ho Chi Minh City 602
Frankfurt am Main 548
Milan 546
Hanoi 466
Wilmington 345
Dublin 343
Chandler 329
New York 276
Beijing 248
Dearborn 229
Los Angeles 227
Santa Clara 201
Hefei 195
Munich 165
Woodbridge 152
Houston 149
Princeton 134
Fairfield 130
Nanjing 118
Vienna 108
Seoul 95
Jakarta 94
Moscow 89
Shanghai 89
Seattle 81
Chicago 76
Buffalo 72
Guangzhou 72
Jacksonville 72
Helsinki 69
São Paulo 69
Boardman 63
Vilnius 58
Ha Long 53
Haiphong 51
The Dalles 50
Dong Ket 49
Da Nang 48
Tokyo 48
Rome 45
Denver 44
Hải Dương 44
Biên Hòa 38
Carate Brianza 38
London 37
Montreal 37
Toronto 37
Ninh Bình 35
Nuremberg 35
Quận Bình Thạnh 34
Pune 33
Warsaw 33
Brooklyn 32
Poplar 32
Bắc Ninh 31
Kent 31
Rio de Janeiro 31
Nanchang 30
Orem 30
Shenyang 30
Atlanta 29
Cambridge 29
Can Tho 29
Lawrence 29
Altamura 28
Chennai 27
Melzo 27
Stockholm 27
Vũng Tàu 27
Amsterdam 26
Phoenix 26
Turku 26
Hangzhou 24
Mexico City 24
Thái Nguyên 24
Council Bluffs 22
Bắc Giang 21
Falls Church 21
Shangdi 21
Brussels 20
Ottawa 20
Quận Một 20
Tianjin 20
Johannesburg 19
Zhengzhou 19
Lappeenranta 18
Boston 17
Jinan 17
Kunming 17
Lang Son 17
Sacramento 17
Andover 16
Changsha 16
Florence 16
Mainz 16
Totale 14.359
Nome #
CIPN and its mechanism of development 516
Paclitaxel alters the microvascular network in the central and peripheral nervous system of rats with chemotherapy-induced painful peripheral neuropathy 505
Morphofunctional characterisation of axonal damage in different rat models of chemotherapy-induced peripheral neurotoxicity: the role of nerve excitability testing 442
Peripheral neuropathy induced by microtubule-targeted chemotherapies: Insights into acute injury and long-term recovery 391
Effect of age on metabolomic changes in a model of paclitaxel‐induced peripheral neurotoxicity 387
Oxaliplatin-induced peripheral neurotoxicity: molecular insights 377
Human Intravenous Immunoglobulin Alleviates Neuropathic Symptoms in a Rat Model of Paclitaxel-Induced Peripheral Neurotoxicity 377
Susceptibility of different mouse strains to oxaliplatin peripheral neurotoxicity: Phenotypic and genotypic insights 370
High-dose intravenous immunoglobulins reduce nerve macrophage infiltration and the severity of bortezomib-induced peripheral neurotoxicity in rats 365
Angiogenesis-Related New Mechanisms for Chemotherapy-Induced Painful Peripheral Neuropathy in the Rat 350
OXALIPLATIN-INDUCED PERIPHERAL NEUROTOXICITY IN MOUSE MODELS: DIFFERENT TREATMENT SCHEDULES AND FOCUS ON OXIDATIVE STRESS 346
Effect of age on metabolomic changes in a model of paclitaxel-induced neurotoxicity 332
Topiramate prevents oxaliplatin-related axonal hyperexcitability and oxaliplatin induced peripheral neurotoxicity 330
Ion Channel and Transporter Involvement in Chemotherapy-Induced Peripheral Neurotoxicity 327
Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of Chemotherapy-Induced Peripheral Neurotoxicity 319
Calmangafodipir reduces sensory alterations and prevents intraepidermal nerve fibers loss in a mouse model of oxaliplatin induced peripheral neurotoxicity 314
Role of Organic Transporters 1 and 2 in Cisplatin mediated neurotoxicity 313
The relevance of multimodal assessment in experimental oxaliplatin-induced peripheral neurotoxicity 306
CENTRAL AND PERIPHERAL MICROVASCULAR NETWORK IS ABNORMAL IN RATS WITH PAINFUL-CHEMOTHERAPY INDUCED NEUROPATHY: NEW PATHOPHYSIOLOGICAL MECHANISMS OVER THE HORIZON? 303
Molsidomine provides neuroprotection against vincristine-induced peripheral neurotoxicity through soluble guanylyl cyclase activation 289
Investigation of Supraspinal Plasticity in a Rat Model of Painful Paclitaxel-induced Peripheral Neuropathy 287
Givinostat-Liposomes: Anti-Tumor Effect on 2D and 3D Glioblastoma Models and Pharmacokinetics 287
Oxaliplatin-induced neuropathy occurs through impairment of haemoglobin proton buffering and is reversed by carbonic anhydrase inhibitors 277
Neuronopathies and polyneuropathies: a ready to use translational neurophysiological protocol in rodent models 268
Molsidomine reduces the severity of Vincristine-induced peripheral neurotoxicity in rats 264
ITF6475, a New Histone Deacetylase 6 Inhibitor, Prevents Painful Neuropathy Induced by Paclitaxel 261
The validation of neuroactive drug selection based on combinatorial screening in bortezomib-induced neurotoxicity models. 257
Sodium-Calcium Exchanger 2: A Pivotal Role in Oxaliplatin Induced Peripheral Neurotoxicity and Axonal Damage? 255
Neurofilament light chain as disease biomarker in a rodent model of chemotherapy induced peripheral neuropathy 252
Translation of paclitaxel-induced peripheral neurotoxicity from mice to patients: the importance of model selection 249
Topiramate possible double efficacy profile: Oxaliplatin-induced peripheral neurotoxicity prevention and anticancer synergic action 249
Paclitaxel, but Not Cisplatin, Affects Satellite Glial Cells in Dorsal Root Ganglia of Rats with Chemotherapy-Induced Peripheral Neurotoxicity 247
Assessment of oxaliplatin-induced peripheral neurotoxicity with different treatment schedules 246
Morpho-Functional Characterisation of the Rat Ventral Caudal Nerve in a Model of Axonal Peripheral Neuropathy 245
Nerve Excitability Testing to Unravel Chemotherapy Induced Peripheral Neurotoxicity (CIPN) Pathogenesis: Altered Axonal Excitability as a Possible Pivotal Event Related to Platinum Compounds and Taxanes 245
An in vivo and in vitro neurophysiological approach to acute and chronic oxaliplatin-induced peripheral neurotoxicity 244
Dorsal Root Ganglia Neurons Morphometry Analysing Method Optimization 237
Sensory-motor paclitaxel polyneuropathy characterization in a rat model 237
Morphological and functional study of the caudal nerve in a rat model of peripheral neuropathy 235
EVALUATION OF SATELLITE GLIAL CELLS CHANGES IN DORSAL ROOT GANGLIA IN CHEMOTHERAPY-INDUCED NEUROTOXICITY MODELS 233
Animal Models for the Study of Human Central and Peripheral Nervous System Diseases 229
Morphological and functional assessment of NCX2 potential role in axonal damage related to Oxaliplatin 227
Study of perpheral neurotoxicity of different doses of oxaliplatin in cd1 mice 227
Reply to a comment paper on the published paper by canta, a. Et al: “calmangafodipir reduces sensory alterations and prevents intraepidermal nerve fibers loss in a mouse model of oxaliplatin induced peripheral neurotoxicity”—antioxidants 2020, 9, 594 227
Systems Pharmacology Modeling Identifies a Novel Treatment Strategy for Bortezomib-Induced Neuropathic Pain 226
Oxaliplatin induced peripheral neurotoxicity (OIPN) and ion unbalance: the perilous link between acute and chronic neurotoxicity. 218
Morphology meets function to unravel Oxaliplatin Induced Peripheral Neurotoxicity (OIPN) 217
NCX2 modulation to prevent axonal damage related to Oxaliplatin-induced peripheral neurotoxicity 216
NEUROINFLAMMATION AS A POTENTIAL TARGET FOR CIPN DIAGNOSTIC AND TREATMENT 213
Satellite Glial Cells in Chemotherapy Induced Peripheral Neuropathy 213
Genetic factors influencing the development of vincristine-induced neurotoxicity 213
In vivo study of Carfilzomib-Induced Neuropathy 209
Studying the caudal nerve anatomy and physiology to refine detection of peripheral nerve damage in rodent models. 208
Multimodal experimental approach to the study of human neurological diseases 205
MORPHOLOGICAL AND METABOLOMIC CHANGES IN PIPN 201
7T MRI first exploitation in a chemotherapy induced peripheral neurotoxicity in vivo model. 200
Inhibition of NHE1 transport activity and gene transcription in DRG neurons in oxaliplatin-induced painful peripheral neurotoxicity 198
Paclitaxel alters angiogenesis in the peripheral and central nervous system of neuropathic rats 196
EVALUATION OF THE EFFICACY OF PERIPHAGEN NEUROTROPHIN-3 EXPRESSING VECTOR FOR OXALIPLATIN INDUCED PERIPHERAL NEUROPATHY. 193
Central and peripheral neoangiogenesis in paclitaxel-induced painful peripheral neuropathy 192
ACCURATE NEUROPHYSIOLOGICAL MONITORING FOR SENSORY NEUROPATHY IN MOUSE MODELS OF CHEMOTHERAPY INDUCED PERIPHERAL NEUROTOXICITY 190
INVESTIGATING THE INVOLVEMENT OF SATELLITE GLIAL CELLS IN PACLITAXEL-INDUCED PERIPHERAL NEUROTOXICITY 189
Tackling Oxaliplatin Induced Peripheral neurotoxicity: from bed to bench side and back. 187
USING A 3D APPROACH TO DESCRIBE CELL POPULATIONS IN THE RAT DORSAL ROOT GANGLIA 182
Intravenous Immunoglobulin Preparation Attenuates Pain Behaviors in a Wistar Rat Model of Bortezomib-Induced Peripheral Neuropathy 181
Oxaliplatin-Induced Peripheral Neurotoxicity: Morphological Characterization In Different Mouse Strains 181
Metabolomics assessment in a mice model ofoxaliplatin-induced peripheral neurotoxicity 177
Peripheral neurotoxicity induced by cisplatin: a possible role of OCT2 gene 176
Ivig Effect In A Wistar Rat Model Of Bortezomib-Induced Peripheral Neuropathy 176
Topiramate Prevents Oxaliplatin Neurotoxicity in a rat model 176
The relevance of morphology in experimental oxaliplatin-induced peripheral neurotoxicity 176
ERIBULIN, PACLITAXEL, IXABEPILONE AND VINORELBINE-INDUCED PERIPHERAL NEUROPATHY IN MICE: INSIGHTS IN LONG-TERM RECOVERY 175
Effect of preventive and therapeutic treatment of ghrelin agonist HM01 on the peripheral neurotoxicity induced by bortezomib in wistar rats. 173
Blood neurofilament light chains as a potential damage marker in chemotherapy-induce peripheral neuropathy rodent models 172
NERVE EXCITABILITY TESTING AS THE LINK BETWEEN ANATOMY AND PHYSIOLOGY: AXONAL EXCITABILITY TESTING TO TEST IN VIVO MECHANISMS OF PERIPHERAL NERVE DAMAGE. 170
The severity of oxaliplatin neurotoxicity is related to differential expression of a solute transporter in mice 166
High resolution MRI in exploring peripheral nerve anatomy and axonal damage in rodent models 165
Oxaliplatin induced peripheral neurotoxicity (OIPN): a translational approach for drug discovery. 165
Oxaliplatin neurotoxicity: morpho-functional approach 163
Acute and chronic Oxaliplatin-induced peripheral neurotoxicity: two sides of the same coin 161
Ghrelin agonist HM01 attenuates chemotherapy-induced neurotoxicity in rodent models 161
Oxaliplatin Neurotoxicity is related to SLC4A1 Expression in BALB/c Mice Dorsal Root Ganglia 156
INVESTIGATION OF AGING EFFECTS ON NERVE DAMAGE IN AN ANIMAL MODEL OF PACLITAXEL-INDUCED PERIPHERAL NEUROPATHY 154
An innovative traslational approach to oxaliplatin induced peripheral neurotoxicity in animal models: nerve excitability testing. 143
STANDARD AND ADVANCED NEUROPHYSIOLOGY SET UP IN MOUSE MODELS: SENSORY RECORDINGS AND NERVE EXCITABILITY TESTING OF THE CAUDAL NERVE. 141
REFINEMENT OF MORPHOLOGICAL ANALYSIS OF THE CAUDAL NERVE IN A RODENT MODEL OF AXONAL DAMAGE WITH 7T MRI 140
Topiramate neuroprotectant effects against oxaliplatin induced peripheral neurotoxicity 139
Nerve Excitability Testing: An In Vivo Translational Approach To Investigate Oxaliplatin Induced Peripheral Neurotoxicity Pathogenesis And Treatment 134
Neurofilament light protein: a blood biomarker of neurodegeneration in chemotherapy-induced peripheral neurotoxicity. 134
MORPHOFUNCTIONAL CHARACTERIZATION OF CIPN 132
Oxaliplatin induced peripheral neurotoxicity: nerve excitability testing full profile in a long term toxicity animal study 131
Oxaliplatin induced Peripheral Neurotoxicity (OIPN): a Rat Model that full encompasses all OIPN Phenomena 128
Oxaliplatin-Induced Peripheral Neurotoxicity: a Role for Genomics? 126
Mitochondrial Dysfunction in Chemotherapy-Induced Peripheral Neuropathy (CIPN) 121
Management of Side Effects in the Personalized Medicine Era: Chemotherapy-Induced Peripheral Neurotoxicity 114
New mechanisms of neurotoxicity related to oxaliplatin chemotherapy in mice 111
Can different Mice Strains be differently susceptible to Oxaliplatin-Induced Peripheral Neuropathy? 110
TOPIRAMATE PREVENTS OXALIPLATIN ACUTE PERIPHERAL NEUROTOXICITY. 99
The Link between Bench and Bed-Side: “clinical” neurophysiological approach to a rat model of neuropathy 93
null 80
Totale 22.610
Categoria #
all - tutte 71.736
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 71.736


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.313 0 0 0 0 0 223 220 236 157 103 140 234
2021/20221.106 111 133 110 97 93 104 49 49 44 52 79 185
2022/20231.884 187 371 239 174 166 306 63 75 136 41 82 44
2023/20241.561 69 61 73 92 156 358 246 104 77 39 47 239
2024/20255.197 241 501 470 235 403 283 438 187 578 711 408 742
2025/20268.511 2.210 1.469 1.978 1.301 1.171 382 0 0 0 0 0 0
Totale 22.878